Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22434609 | 0.86 | LTA4H (0.49) | L3MBTL1CCNCCDK8PDK2SMN1; SMN2 | |
| SCHEMBL27081066 | 0.83 | L3MBTL1 (0.62) | L3MBTL1KMT2AMEN1NPC1 | |
| SCHEMBL14220752 | 0.81 | SMN1; SMN2 (0.67) | L3MBTL1NPC1TP53HPGDHTT | |
| SCHEMBL9920173 | 0.81 | RAB9A (0.50) | L3MBTL1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL27750359 | 0.81 | L3MBTL1 (0.75) | L3MBTL1KMT2AMEN1NPC1TP53 | |
| SCHEMBL3127329 | 0.81 | CCNC (0.43) | L3MBTL1CCNCCDK8PDK2SMN1; SMN2 | |
| SCHEMBL169689 | 0.79 | L3MBTL1 (0.72) | L3MBTL1KMT2AMEN1NPC1TP53 | |
| SCHEMBL11128265 | 0.79 | L3MBTL1 (0.72) | L3MBTL1KMT2AMEN1NPC1TP53 | |
| SCHEMBL1806524 | 0.79 | L3MBTL1 (1.00) | L3MBTL1KMT2AMEN1NPC1TP53 | |
| SCHEMBL3951838 | 0.79 | L3MBTL1 (0.66) | L3MBTL1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850275-B | Method for synthesizing zolpidem by utilizing photocatalytic three-component reaction | 江苏农牧科技职业学院 | 2024-09-13 | — | — | CN | disclosed |
| CN-114892188-B | Electrochemical synthesis method of zolpidem | 江苏农牧科技职业学院 | 2023-10-03 | — | — | CN | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | L3MBTL1 4461/4885KMT2A 774/4885MEN1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.